Pharmaceuticals, Biotechnology and Life Sciences
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option…
– Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – –…
Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to…
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026;…
Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued…
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in…
LEAWOOD, Kan., Jan. 09, 2026 (GLOBE NEWSWIRE) — Etienna Bio, Inc., a biotechnology company focused on next-generation autologous and cell-enabled…
– Rapidly transforming into a leading global biopharma companyCOPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq:…
Strong Balance Sheet Reflects Revenue Growth and New $125M Five-Year FacilityNEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited…